Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis
- 24 August 2018
- journal article
- letter
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (4) , 1314-1316
Abstract
No abstract availableFunding Information
- Division of Intramural Research, National Institutes of Health, National Institute of Allergy and Infectious Diseases
This publication has 9 references indexed in Scilit:
- Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observationsAllergy, 2017
- Mastocytosis: 2016 updated WHO classification and novel emerging treatment conceptsBlood, 2017
- Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paperAllergy, 2015
- Epidemiology, Prognosis, and Risk Factors in MastocytosisImmunology and Allergy Clinics of North America, 2014
- Severe Life-Threatening or Disabling Anaphylaxis in Patients with Systemic Mastocytosis: A Single-Center ExperienceInternational Archives of Allergy and Immunology, 2011
- OMALIZUMAB IN IDIOPATHIC ANAPHYLAXISAnnals of Allergy, Asthma & Immunology, 2009
- Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patientsAllergy, 2008
- KIT D816V–associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entitiesJournal of Allergy and Clinical Immunology, 2007
- Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosisJournal of Allergy and Clinical Immunology, 2007